LTD.;AHN-GOOK PHARMACEUTICAL CO., LTD.;AHN-GOOK PHARMACEUTICAL CO.;안국약품 주식회사
发明人:
AUH, Jin,어진,JEONG, Hyeon Gun,정현근,LEE, Jong-Kwon,이종권,YOUN, Ju Yong,윤주용,SHIN, Je Yong,신제용
申请号：
KRKR2013/004039
公开号：
WO2013/169007A1
申请日:
2013.05.08
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
The present invention relates to sustained-release complex preparations for the treatment of diabetes with improved drug compliance and to a method for preparing same. More particularly, the present invention relates to sustained-release complex oral preparations for the treatment of diabetes, which comprise: a) an inner layer that includes Metformin or pharmaceutically acceptable salts thereof, sustained-release carriers and a pharmaceutically acceptable excipient； b) an intermediate layer that does not include drugs and that includes a water-soluble polymer； and c) an outer layer that includes sulfonylurea-based drugs and a control release formulation, wherein Carbomer is used as the sustained-release carriers. According to the present invention, complex preparations for the treatment of diabetes, comprising the inner layer including Metformin, the intermediate layer and the outer layer including sulfonylurea-based drugs, use Carbomer as the sustained-release carriers of the inner layer, thus exhibiting the same release pattern as that of Amaryl Mex which has been used in conventional complex preparations for the treatment of diabetes. Furthermore, the greater part of the sustained-release carriers is decomposed after 24 hours, thus avoiding gastrointestinal tract disorders. The weight of the inner layer is minimized to reduce the size of a tablet to allow for ease of medicine taking, thus improving drug compliance of a patient.La présente invention concerne des préparations complexes à libération prolongée pour le traitement du diabète avec une observance médicamenteuse améliorée et un procédé pour préparer celles-ci. Plus particulièrement, la présente invention concerne des préparations orales complexes à libération prolongée pour le traitement du diabète, qui comprennent : a) une couche interne qui comprend de la metformine ou des sels pharmaceutiquement acceptables de celle-ci, des véhicules à libération prolongée et un excipient pharmaceutiquement acceptable
